CheckMate 722

9 evidence topics · 2 sources

Objective

Location and study date

Study design

Masking design

“open-label” (opens the source at this quote in a new tab)

Eligibility criteria

Treatment

Nivolumab dose with chemotherapy

“360 mg” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using progression-free survival as the primary endpoint

Statistical analysis description

Number of participants (Planned and analyzed)

Planned and randomized participants

Quantity	Quoted count
Original enrollment target	“500”
Revised enrollment target	“270”
Randomized participants	“294”

Description of analysis sets

Estimated statistical power with observed PFS events

“76%” (opens the source at this quote in a new tab)

Results

Participant disposition

Treated participants

Nivolumab plus chemotherapy	Chemotherapy
“141”	“143”

Baseline characteristics

Efficacy results

Median progression-free survival

Nivolumab plus chemotherapy, months	Chemotherapy, months
“5.6”	“5.4”

Comparator trial: CheckMate 722

“Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

Safety results

Grade 3 or 4 treatment-related adverse events

Nivolumab plus chemotherapy	Chemotherapy
“44.7%”	“29.4%”

Study limitations

Summary

The enrollment target was reduced from 500 to 270 participants, and the estimated power with observed PFS events was 76%. The open-label study did not meet its primary PFS endpoint. Grade 3 or 4 TRAEs were reported in 44.7% versus 29.4%. The trial evaluates nivolumab, not ivonescimab.